Effects of denosumab for bone resorption in the femur after total hip arthroplasty

Effects of denosumab for bone resorption in the femur after total hip arthroplasty - Effects of denosumab for bone resorption in the femur after total hip arthroplasty

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028169

Enrollment

Registered

2017-07-10

Start date

2016-06-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients treated with primary total hip arthroplasty

Interventions

Denosumab: 60 mg once in 6 months by subcutaneous injection. Eldecalcitol: 0.75 micro g once a day orally. These 2 drugs will be continued for 2 years.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Male:20 years old or more, Female: menopause (2) Japanese (3) Osteoarthritis of the hip or Osteonecrosis of the hip (4) No treatment of osteoporosis (5) Independence of daily living (6) Change of bone mineral density is within 10% or decrease of bone mineral density is 10% or more between 1 year and last follow-up. (7) Patients agree to participate in this study with written informed consent.

Exclusion criteria

Exclusion criteria: (1) Severe renal failure (CCr:less than 30mL/min) (2) Hypercalcemea or hypocalcemia (3) Past history of femoral osteotomy (4) Systemic bone disease (5) Patients, who are considered to be inappropriate for this study by doctors.

Design outcomes

Primary

Measure	Time frame
DEXA of the femur	—

Secondary

Measure	Time frame
P1NP, TRAP5b plain radiographs of the hip joint	—

Countries

Japan

Contacts

Public ContactHyonmin Choe

Yokohama City University Department of Orthopaedic Surgery

hyonmin@hotmail.com045-787-2655

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026